Clinical Trial Update: Classroom Study of SPN-812 in Children With ADHD [Phase 3]

View source ↗

Summary

A Phase 3 trial of SPN-812 in children with ADHD was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• SPN-812 (viloxazine)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: ADHD | Phase 3 | Status: WITHDRAWN